Author:
Howell Sacha J,Casbard Angela,Carucci Margherita,Ingarfield Kate,Butler Rachel,Morgan Sian,Meissner Magdalena,Bale Catherine,Bezecny Pavel,Moon Sarah,Twelves Chris,Venkitaraman Ramachandran,Waters Simon,de Bruin Elza C,Schiavon Gaia,Foxley Andrew,Jones Robert H
Reference31 articles.
1. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status;Howlader;J Natl Cancer Inst,2014
2. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5);Cardoso;Ann Oncol,2020
3. Maximising the potential of AKT inhibitors as anti-cancer treatments;Brown;Pharmacol Ther,2017
4. Clinical development of AKT inhibitors and associated predictive biomarkers to guide patient treatment in cancer medicine;Coleman;Pharm Genomics Pers Med,2021
5. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial;Baselga;Lancet Oncol,2017
Cited by
77 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献